Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The Absence of CYP3A5{*}3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects

Full text
Tanno, Luciana Kase [1] ; Kerr, Daniel Shikanai [2, 3] ; dos Santos, Bernardo [4] ; Talib, Leda Leme [2, 3] ; Yamaguti, Celia [5] ; Rodrigues, Helcio [5] ; Gattaz, Wagner Farid [2, 3] ; Kalil, Jorge [1, 5]
Total Authors: 8
[1] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo - Brazil
[3] Univ Sao Paulo, Ctr Interdisciplinary Res Appl Neurosci NAPNA, Sao Paulo - Brazil
[4] Univ Sao Paulo, Sch Nursing, Sao Paulo - Brazil
[5] Univ Sao Paulo, Clin Immunol & Allergy Div, Lab Immunol LIM 19, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: PLoS One; v. 10, n. 8 AUG 20 2015.
Web of Science Citations: 6

Although aromatic anticonvulsants are usually well tolerated, they can cause cutaneous adverse drug reactions in up to 10% of patients. The clinical manifestations of the antiepileptics-induced hypersensitivity reactions (AHR) vary from mild skin rashes to severe cutaneous drug adverse reactions which are related to high mortality and significant morbidity. Genetic polymorphisms in cytochrome P450 genes are associated with altered enzymatic activity and may contribute to the risk of AHR. Here we present a case-control study in which we genotyped SNPs of CYP2C19, 2C9 and 3A5 of 55 individuals with varying severities of AHR, 83 tolerant, and 366 healthy control subjects from Sao Paulo, Brazil. Clinical characterization was based on standardized scoring systems and drug patch test. All in vivo investigation followed the ENDA (European Network of Drug Allergy) recommendations. Genotype was determined by real time PCR using peripheral blood DNA as a template. Of all 504 subjects, 65% were females, 45% self-identified as Afro-American, 38% as Caucasian and 17% as having non-African mixed ascendancy. Amongst 55 subjects with AHR, 44 had severe cutaneous drug adverse reactions. Of the 46 drug patch tests performed, 29 (63%) were positive. We found a strong association between the absence of CYP3A5{*}3 and tolerant subjects when compared to AHR (p = 0.0002, OR = 5.28 {[}CI95% 2.09-14.84]). None of our groups presented positive association with CYP2C19 and 2C9 polymorphisms, however, both SNPs contributed to separation of cases and tolerants in a Classification and Regression Tree. Our findings indicate that drug metabolism genes can contribute in the tolerability of antiepileptics. CYP3A5{*}3 is the most prevalent CYP3A5 allele associated with reduced enzymatic function. The current study provides evidence that normal CYP3A5 activity might be a protective factor to aromatic antiepileptics-induced hypersensitivity reactions in Brazilian subjects. (AU)

FAPESP's process: 11/22748-1 - Association study of genetic factors in subjects with delay hypersensitivity reactions to aromatic antiepileptics
Grantee:Jorge Elias Kalil Filho
Support type: Regular Research Grants